Natriuretic Peptides as the Basis of Peptide Drug Discovery for Cardiovascular Diseases
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Cardiovascular diseases (CVDs) are the leading global cause of death, accounting for more than 17.6 million deaths per year in 2016, a number that is expected to grow to more than 23.6 million by 2030. While many technologies are currently under investigation to improve the therapeutic outcome of CVD complications, only a few medications have been approved. Therefore, new approaches to treat CVD are urgently required. Peptides regulate numerous physiological processes, mainly by binding to specific receptors and inducing a series of signals, neurotransmissions or the release of growth factors. Importantly, peptides have also been shown to play an important role in the circulatory system both in physiological and pathological conditions. Peptides, such as angiotensin II, endothelin, urotensin-II, urocortins, adrenomedullin and natriuretic peptides have been implicated in the control of vascular tone and blood pressure as well as in CVDs such as congestive heart failure, atherosclerosis, coronary artery disease, and pulmonary and systemic hypertension. Hence it is not surprising that peptides are becoming important therapeutic leads in CVDs. This article will review the current knowledge on peptides and their role in the circulatory system, focusing on the physiological roles of natriuretic peptides in the cardiovascular system and their implications in CVDs.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
---|---|
Enthalten in: |
Current topics in medicinal chemistry - 20(2020), 32 vom: 02., Seite 2904-2921 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lerner, Yana [VerfasserIn] |
---|
Links: |
---|
Themen: |
Cardiovascular diseases |
---|
Anmerkungen: |
Date Completed 01.07.2021 Date Revised 01.07.2021 published: Print Citation Status MEDLINE |
---|
doi: |
10.2174/1568026620666201013154326 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM316205176 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM316205176 | ||
003 | DE-627 | ||
005 | 20231225160559.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2174/1568026620666201013154326 |2 doi | |
028 | 5 | 2 | |a pubmed24n1053.xml |
035 | |a (DE-627)NLM316205176 | ||
035 | |a (NLM)33050863 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Lerner, Yana |e verfasserin |4 aut | |
245 | 1 | 0 | |a Natriuretic Peptides as the Basis of Peptide Drug Discovery for Cardiovascular Diseases |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 01.07.2021 | ||
500 | |a Date Revised 01.07.2021 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
520 | |a Cardiovascular diseases (CVDs) are the leading global cause of death, accounting for more than 17.6 million deaths per year in 2016, a number that is expected to grow to more than 23.6 million by 2030. While many technologies are currently under investigation to improve the therapeutic outcome of CVD complications, only a few medications have been approved. Therefore, new approaches to treat CVD are urgently required. Peptides regulate numerous physiological processes, mainly by binding to specific receptors and inducing a series of signals, neurotransmissions or the release of growth factors. Importantly, peptides have also been shown to play an important role in the circulatory system both in physiological and pathological conditions. Peptides, such as angiotensin II, endothelin, urotensin-II, urocortins, adrenomedullin and natriuretic peptides have been implicated in the control of vascular tone and blood pressure as well as in CVDs such as congestive heart failure, atherosclerosis, coronary artery disease, and pulmonary and systemic hypertension. Hence it is not surprising that peptides are becoming important therapeutic leads in CVDs. This article will review the current knowledge on peptides and their role in the circulatory system, focusing on the physiological roles of natriuretic peptides in the cardiovascular system and their implications in CVDs | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Cardiovascularsystem | |
650 | 4 | |a Cardiovascular diseases | |
650 | 4 | |a Circulatory system | |
650 | 4 | |a Drug discovery | |
650 | 4 | |a Natriuretic peptides | |
650 | 4 | |a Peptides | |
650 | 4 | |a Peptidomimetics | |
650 | 4 | |a Therapeutic | |
650 | 7 | |a Natriuretic Peptides |2 NLM | |
700 | 1 | |a Hanout, Wessal |e verfasserin |4 aut | |
700 | 1 | |a Ben-Uliel, Shulamit Fluss |e verfasserin |4 aut | |
700 | 1 | |a Gani, Samar |e verfasserin |4 aut | |
700 | 1 | |a Leshem, Michal Pellach |e verfasserin |4 aut | |
700 | 1 | |a Qvit, Nir |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current topics in medicinal chemistry |d 2001 |g 20(2020), 32 vom: 02., Seite 2904-2921 |w (DE-627)NLM117790141 |x 1873-4294 |7 nnns |
773 | 1 | 8 | |g volume:20 |g year:2020 |g number:32 |g day:02 |g pages:2904-2921 |
856 | 4 | 0 | |u http://dx.doi.org/10.2174/1568026620666201013154326 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 20 |j 2020 |e 32 |b 02 |h 2904-2921 |